Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Schockwave ™ gegen chirurgische Endarterektomie für eine verkalkte Stenose der häufigen häufigen Femurarterie: Vergleich von Wirksamkeit, Sicherheit und langfristigen Ergebnissen (Shockify)

4. November 2026 aktualisiert von: Baylor Research Institute

The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Texas
      • Plano, Texas, Vereinigte Staaten, 75093
        • Baylor Scott & White The Heart Hospital - Plano

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):

  1. CFA atherosclerotic stenosis 60-100%
  2. Moderate to severe calcification reported on imaging
  3. Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5
  4. Failing conservative therapy
  5. Operative candidate for CFE prior to enrollment
  6. ≥18 years of age

Exclusion Criteria:

A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:

  1. History of CFE or bypass in affected limb
  2. Thrombosis of affected CFA
  3. Aneurysm in the common femoral artery of target limb
  4. Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months)
  5. Any preceding percutaneous cardiovascular intervention within 2 weeks
  6. Inability to tolerate DAPT
  7. Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count <100,000/µL
  8. Uncontrolled diabetes (HbA1c ≥10.0%)
  9. Non-ambulatory
  10. Extensive tissue loss requiring amputation or salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations
  11. MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segment deviation and troponin higher than 2 times the upper limit of normal))
  12. Stroke within 3 months (defined as sudden transient or irreversible focal neurological deficit resulting from a cerebrovascular cause)
  13. Pregnant

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Shockwave Catheter

Shockwave™ Intravenous Lithotripsy (IVL)+ DCB (Drug Coated Balloon)

Shockwave™ IVL + DCB procedure

Aktiver Komparator: surgical endarterectomy

Surgery should be performed with patch angioplasty, with or without profunda femoris endarterectomy.

Standard CFA endarterectomy

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Klinisch angetriebene Zielläsionsrevaskularisation (CDTLR (symptomgetriebene Wiederholungsrevaskularisierung der Indexläsion))
Zeitfenster: Verfahrensdatum bis 1 Jahr nach der OP
Verfahrensdatum bis 1 Jahr nach der OP
Restenose zu ≥ 50% der Zielläsion auf Angiographie oder Follow-up-Ultraschall
Zeitfenster: Verfahrensdatum bis 1 Jahr nach der OP
Verfahrensdatum bis 1 Jahr nach der OP
Freiheit vom perioperativen Tod
Zeitfenster: Verfahrensdatum bis 30 Tage nach der OP
Verfahrensdatum bis 30 Tage nach der OP
Freiheit von großen unerwünschten kardiovaskulären Ereignissen (Kennmaschine (Schlaganfall, Myokardinfarkt (MI), Herz -Kreislauf -Tod))
Zeitfenster: Verfahrensdatum bis 30 Tage nach der OP
Verfahrensdatum bis 30 Tage nach der OP
Freedom from major adverse events
Zeitfenster: Procedure date through 6 months post-op
  1. Acute occlusion of the target lesion

  2. Flow-limiting dissection of the target lesion

  3. Symptomatic thrombus or embolus in treated limb requiring treatment

  4. Unplanned percutaneous/surgical revascularization or amputation above the ankle of the treated limb

  5. Access/surgical site complications

    1. Bleeding events (specify Bleeding Academic Research Consortium (BARC) type - see Appendix 18.2)
    2. Surgical site infection requiring medication or surgery, wound dehiscence, patch/arterial infection, lymphatic leak requiring surgery
Procedure date through 6 months post-op

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mortalität
Zeitfenster: Verfahrensdatum bis 1 Jahr nach der OP
Verfahrensdatum bis 1 Jahr nach der OP
Intraoperative Bluttransfusion> 4 Minuten
Zeitfenster: Intra-op
Intra-op
Verfahrensdauer (Minuten)
Zeitfenster: Intra-op
Intra-op
Aufenthaltsdauer (Tage)
Zeitfenster: Verfahrensdatum bis 1 Jahr nach der OP
Verfahrensdatum bis 1 Jahr nach der OP
Postoperative Anämie, die Bluttransfusion erfordert
Zeitfenster: Verfahrensdatum bis 30 Tage nach der OP
Verfahrensdatum bis 30 Tage nach der OP
Rückübernahmen
Zeitfenster: 30 Tage nach der Op, 30 Tage nach der Entlastung
30 Tage nach der Op, 30 Tage nach der Entlastung
Kehren Sie in die Operationssaal / Angiography Suite zurück
Zeitfenster: 30 Tage nach der Op
30 Tage nach der Op
Rutherford Chronic Limb Ischemia (CLI) Category
Zeitfenster: 30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op

https://www.ncbi.nlm.nih.gov/books/NBK553864/table/ch20.Tab2/#

Stage 0 - Asymptomatic. Stage 1 - Mild claudication - Completes treadmill exercise; Ankle Pressure (AP) after exercise >50 mmHg but at least 20 mmHg lower than resting value.

Stage 2 - Moderate claudication - Between categories 1 and 3. Stage 3 - Severe claudication - Cannot complete standard treadmill exercise and AP after exercise <50 mm Hg.

Stage 4 - Ischemic rest pain - Resting AP <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); Toe Pressure (TP) < 30 mm Hg.

Stage 5 - Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia- Resting AP < 60 mm Hg, ankle or metatarsal PVR flat or barely pulsatile; TP < 40 mm Hg Stage 6 - Major tissue loss-extending above TM level, functional foot no longer salvageable - Same as category 5

30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
Treatment satisfaction and quality of life (PAQ)
Zeitfenster: Pre-op, 30 days post-op, 6 months post-op, 1 year post-op

Measured by the Peripheral Artery Questionnaire (PAQ), a 20-question questionnaire measuring peripheral vascular disease affect on quality of life. Questionnaires may be completed in-person or via phone call conducted by the study coordinator.

Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
Access/surgical site complications
Zeitfenster: 30 days post-op, 6 months post-op
  1. Superficial wound infection
  2. Deep wound infection
  3. Wound dehiscence
  4. Pseudoaneurysm identified on physical exam, imaging or angiography
  5. Hematoma identified on physical exam, imaging or angiography
30 days post-op, 6 months post-op
Pneumonia (number of cases)
Zeitfenster: Procedure date through 30 days post-op

Patients must meet criteria from both sections:

Radiology: One definitive chest radiological exam (x-ray or CT) with at least one of the following:

  • New or progressive and persistent infiltrate
  • Consolidation or opacity

Patients with underlying pulmonary or cardiac disease require two serial chest radiological exams (x-ray or CT) taken no less than 12 hours apart, but no more than 7 days apart.

Signs/Symptoms/Laboratory: at least one of the following:

  • Fever (>38 C) with no other recognized cause

  • Leukopenia (<4000 WBC/mm3) or leukocytosis (≥12,000 WBC/mm3)

  • For adults ≥ 70 years old, altered mental status with no other recognized cause and at least one of the following:

    1. 5% Bronchoalveolar lavage (BAL)
    2. Positive growth in blood culture not related to another source of infection
    3. Positive growth in culture of pleural fluid
    4. Positive quantitative culture from minimally contaminated lower respiratory tract (LRT) specimen
Procedure date through 30 days post-op
Prolonged intubation
Zeitfenster: Procedure date through 30 days post-op

Intubation greater than 48 hours postoperatively

Procedure date through 30 days post-op
Urinary tract infection
Zeitfenster: Procedure date through 30 days post-op

Must meet one of the following TWO criteria within 30 days of the operation:

  • fever (>38C)
  • urgency
  • frequency
  • dysuria
  • suprapubic tenderness

AND urine culture of >105 colonies/mL urine with no more than two species of organisms

OR two of the following:

  • fever (>38C)
  • urgency
  • frequency
  • dysuria
  • suprapubic tenderness

AND any of the following:

  • dipstick test positive for leukocyte esterase and/or nitrite
  • pyuria (>10WBCs/mL or >3 WBC/hpf of unspun urine)
  • organisms seen on Gram stain of unspun urine
  • two urine cultures with repeated isolation of the same uropathogen with >102 colonies/mL urine in non-voided specimen
  • urine culture with <105 colonies/mL urine of single uropathogen in patient being treated with appropriate antimicrobial therapy
  • physician's diagnosis
  • physician institutes appropriate antimicrobial therapy
Procedure date through 30 days post-op
Sepsis
Zeitfenster: Procedure date through 30 days post-op

The disorder spectrum spans from relatively mild physiologic abnormalities to septic shock. The most significant level is reported using the following criteria: SIRS (Systemic Inflammatory Response Syndrome), clinically recognized by the presence of two or more of the following in the same time frame:

Temp >38 degrees C or 90 bpm RR >20 breaths/min or PaCO2 12,000 cell/mm3, 10% immature (band) forms anion gap acidosis. Report if the patient has clinical signs and symptoms of SIRS listed above and meets either A or B:

A. One of the following:

  • Positive blood culture
  • Clinical documentation of purulence or positive culture

B. Suspected pre-operative infection or bowel infarction leading to the surgical procedure. Procedural findings must confirm this suspected diagnosis with one or more of the following:

  • Confirmed infarcted bowel requiring resection
  • Purulence in the operative site
  • Enteric contents in the operative site
  • Positive intra-operative cultures
Procedure date through 30 days post-op
Septic shock
Zeitfenster: Procedure date through 30 days post-op

Report this variable if the patient has sepsis AND documented organ and/or circulatory dysfunction. Examples of organ dysfunction include: oliguria, acute alteration in mental status, acute respiratory distress. Examples of circulatory dysfunction include: hypotension, requirement of inotropic or vasopressor agents. The presence of pneumatosis along with the presence of SIRS is assigned.

Procedure date through 30 days post-op
Graft failure
Zeitfenster: Procedure date through 30 days post-op

Mechanical failure of an extracardiac graft or prosthesis including myocutaneous flaps and skin grafts requiring return to the operating room, interventional radiology or a balloon angioplasty within 30 days of the operation.

Procedure date through 30 days post-op
Cardiac arrest
Zeitfenster: Procedure date through 30 days post-op

The absence of cardiac rhythm or presence of chaotic cardiac rhythm, intraoperatively or postoperatively, which results in a cardiac arrest requiring the initiation of CPR, which includes chest compressions. Patients are included who are in a pulseless VT or Vfib in in which defibrillation is performed and PEA arrests requiring chest compressions. Patients with automated implantable cardioverter defibrillator (AICD) that fire but the patient has no loss of consciousness should be excluded.

Procedure date through 30 days post-op
Myocardial infarction
Zeitfenster: Procedure date through 30 days post-op

Documentation of one or more of the following changes indicative of acute MI:

  • ST elevation >1mm in two or more contiguous leads
  • New left bundle branch block
  • New q-wave in two or more contiguous leads
  • New elevation in troponin greater than 3 times the upper level o f the reference range in the setting of suspected myocardial ischemia
Procedure date through 30 days post-op
Acute kidney injury
Zeitfenster: Procedure date through 30 days post-op

In a patient who did not require dialysis preoperatively, worsening of renal dysfunction postoperatively requiring hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltration

Procedure date through 30 days post-op
Dialysis
Zeitfenster: Procedure date through 30 days post-op

Initiation of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or ultrafiltration in a patient not previously on said therapy preoperatively

Procedure date through 30 days post-op
Deep vein thrombosis
Zeitfenster: Procedure date through 30 days post-op

New diagnosis of blood clot or thrombus within the venous system (superficial or deep) which may be coupled with inflammation and requires treatment. Must be noted within 30 days after the principal operative procedure AND one of the following A or B below:

A.New Diagnosis of a [new] venous thrombosis (superficial or deep), confirmed by a duplex, venogram, CT scan, or any other definitive imaging modality (including direct pathology examination such as autopsy) AND the patient must be treated with anticoagulation therapy and/or placement of a vena cava filter or clipping of the vena cava, or the record indicates that treatment was warranted but there was no additional appropriate treatment option available.

B. As per (A) above, but the patient or decisionmaker has refused treatment. There must be documentation in the medical record of the [patient's] refusal of treatment.

Procedure date through 30 days post-op
Pulmonary embolism
Zeitfenster: Procedure date through 30 days post-op

Lodging of a blood clot in the pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or pelvic venous system. Since there are not always preoperative studies proving that a clot or thrombus was not present preoperatively, the technical specification of the variable requires only a "new diagnosis"- in other words the clot or thrombus was not previously known. A pulmonary embolism must be noted within 30 days after the principal operative procedure AND the following criteria, A AND B below:

A. New diagnosis of a new blood clot in a pulmonary artery

AND

B. The patient has a V-Q scan interpreted as high probability of pulmonary embolism or a positive CT exam, TEE, pulmonary arteriogram, CT angiogram, or any other definitive imaging modality (including direct pathology examination such as autopsy

Procedure date through 30 days post-op

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Sameh Sayfo, MD, Baylor Scott & White The Heart Hospital - Plano
  • Hauptermittler: John Kedora, MD, Baylor Scott & White The Heart Hospital - Plano

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. März 2024

Primärer Abschluss (Tatsächlich)

3. November 2026

Studienabschluss (Geschätzt)

30. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

1. Oktober 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. Februar 2025

Zuerst gepostet (Tatsächlich)

17. Februar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 021-263

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .